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thiBACKGROUND Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or older, diabetes
mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score is recommended
by both American and European guidelines for stroke risk stratiﬁcation in atrial ﬁbrillation (AF), the treatment recom-
mendations for a CHA2DS2-VASc score of 1 are less clear.
OBJECTIVES This study aimed to investigate the risk of ischemic stroke in patients with a single additional stroke
risk factor (i.e., CHA2DS2-VASc score ¼ 1 [males] or 2 [females]) and the impact of different component risk factors.
METHODS We used the National Health Insurance Research Database in Taiwan. Among 186,570 AF patients not
on antiplatelet or anticoagulant therapy, we evaluated males with a CHA2DS2-VASc score of 1 and females with a
CHA2DS2-VASc score of 2. The clinical endpoint was the occurrence of ischemic stroke.
RESULTS Among 12,935 male AF patients with a CHA2DS2-VASc score of 1, 1,858 patients (14.4%) experienced ischemic
stroke during follow-up (5.2  4.3 years), with an annual stroke rate of 2.75%. Ischemic stroke risk ranged from
1.96%/year for men with vascular disease to 3.50%/year for those 65 to 74 years of age. For 7,900 females with AF
and a CHA2DS2-VASc score of 2, 14.9% experienced ischemic stroke for an annual stroke rate of 2.55%. Ischemic stroke
risk increased from 1.91%/year for women with hypertension to 3.34%/year for those 65 to 74 years of age.
CONCLUSIONS Not all risk factors in CHA2DS2-VASc score carry an equal risk, with age 65 to 74 years associated with
the highest stroke rate. Oral anticoagulation should be considered for AF patients with 1 additional stroke risk factor
given their high risk of ischemic stroke. (J Am Coll Cardiol 2015;65:635–42) © 2015 by the American College of
Cardiology Foundation.m the *Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; yInstitute of Clinical
dicine, and Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; zDivision of Hematology and
cology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; xInstitute of Public Health and School of
dicine, National Yang-Ming University, Taipei, Taiwan; kDepartment of Family Medicine, Taipei Veterans General Hospital,
ipei, Taiwan; and the {University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United
gdom. This work was supported in part by grants from the National Science Council (NSC98-2410-H-010-003-MY2) and Taipei
terans General Hospital (V99C1-140, V99A-153, V100D-002-3, V101D-001-2, and V102B-025). Dr. Lip has served as a consultant
Bayer, Astellas, Merck, Sanoﬁ, Bristol-Myers Squibb (BMS)/Pﬁzer, Daiichi-Sankyo, Biotronik, Medtronic, Portola, and
ehringer Ingelheim; and has been on the speakers bureau for Bayer, Bristol-Myers Squibb/Pﬁzer, Boehringer Ingelheim, Daiichi-
nkyo, Medtronic, and Sanoﬁ. All other authors have reported that they have no relationships relevant to the contents of
s paper to disclose. This study is based in part on data from the National Health Insurance Research Database provided by the
ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College
of Cardiology
AF = atrial ﬁbrillation
AHA = American Heart
Association
CHA2DS2-VASc = congestive
heart failure, hypertension,
age 75 years or older, diabetes
mellitus, previous stroke or
transient ischemic attack,
vascular disease, age 65 to
74 years, female
CI = conﬁdence interval
ESC = European Society
of Cardiology
NHIRD = National Health
Insurance Research Database
OAC = oral anticoagulant
agent
Bureau of
pretation a
or National
and Shih-A
Listen to th
You can als
Manuscript
Chao et al. J A C C V O L . 6 5 , N O . 7 , 2 0 1 5
Stroke Risk for a CHA2DS2-VASc Score 1 to 2 F E B R U A R Y 2 4 , 2 0 1 5 : 6 3 5 – 4 2
636A trial ﬁbrillation (AF) is an importantrisk factor for ischemic stroke, andAF-related stroke has a worse prog-
nosis and higher recurrence rate compared
with non–AF-related stroke (1). In 2010, the
CHA2DS2-VASc (congestive heart failure,
hypertension, age 75 years or older, diabetes
mellitus, previous stroke or transient is-
chemic attack, vascular disease, age 65 to
74 years, female) score was ﬁrst proposed
to calculate stroke risk for patients with AF
(2). It has now been well validated in several
independent cohorts (3–9).SEE PAGE 643In 2012, the European Society of Cardi-
ology (ESC) guidelines recommended using
the CHA2DS2-VASc score for stroke risk
stratiﬁcation in AF (10), followed by the
Asia Paciﬁc Heart Rhythm Society, and in2014 by the American College of Cardiology/Amer-
ican Heart Association (ACC/AHA) AF guidelines as
well as the National Institute for Health and Care
Excellence guidelines (11–13). Nonetheless, the
treatment recommendations are not identical in
these different guidelines. In the ESC, Asia Paciﬁc
Heart Rhythm Society, and National Institute for
Health and Care Excellence guidelines, low-risk
patients (CHA2DS2-VASc score of 0 for males, 1 for
females) are not recommended for any antith-
rombotic therapy, whereas oral anticoagulant agents
(OACs) are advised for male AF patients with a
CHA2DS2-VASc score of 1 (10,11,13). The 2014 ACC/
AHA guideline states that “no antithrombotic ther-
apy, aspirin or an OAC” may be considered for AF
patients with a CHA2DS2-VASc score of 1 (class IIb
recommendation) (12). Because being female is a
risk factor, increasing the CHA2DS2-VASc score by 1
point, does that mean all women in the United
States with AF are candidates for OACs?
By deﬁnition, no woman with AF can have a
CHA2DS2-VASc score of 0, thus data are needed
regarding the annual risk of ischemic stroke in
these patients. The objective of the present study
was to investigate the risk of ischemic stroke in
patients with a single additional stroke risk factorNational Health Insurance, Department of Health, and managed
nd conclusions contained herein do not represent those of Bureau
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received September 12, 2014; revised manuscript received Nove(i.e., CHA2DS2-VASc score of 1 for males or 2 for
females) and the impact of different component risk
factors, especially given the limited published data in
Asian patients with AF and minimal risk factors.
METHODS
This retrospective study used the National Health In-
surance Research Database (NHIRD) of the Taiwan
National Health Research Institutes. The National
Health Insurance system is a mandatory universal
program that offers comprehensive medical care
coverage to all Taiwanese residents. Information in
the NHIRD consists of detailed health care data from
more than 23 million enrollees, representing more
than 99% of Taiwan’s population. In this cohort
dataset, the patients’ original identiﬁcation numbers
have been encrypted to protect their privacy, but the
encrypting procedure was consistent, so that a linkage
of the claims belonging to the same patient was
feasible in the NHIRD and can be followed continu-
ously. The large database provided a good opportunity
to retrospectively study the risk of ischemic stroke in
AF patients with a CHA2DS2-VASc score of 1 (for males)
and 2 (for females) with each component of risk factor.
Information about important comorbid conditions
of each individual was retrieved from the medical
claims based on the International Classiﬁcation of
Diseases-Ninth Revision-Clinical Modiﬁcation codes.
We deﬁned patients with a certain disease only when it
was a discharge diagnosis or conﬁrmed more than
twice in an outpatient department. The diagnostic
accuracies of important comorbidities, such as hyper-
tension, diabetes mellitus, heart failure, myocardial
infarction, hyperlipidemia, and chronic obstructive
pulmonary disease, have been validated before (14,15).
STUDY COHORT. From January 1, 1996, to December
31, 2011, a total of 354,649 AF patients 20 years of
age or older were identiﬁed from the NHIRD as the
study population. AF was diagnosed using the Inter-
national Classiﬁcation of Diseases-Ninth Revision-
Clinical Modiﬁcation code (427.31) registered by the
physicians responsible for treatment. To ensure
diagnostic accuracy, we deﬁned patients with AF just
like any other condition: only when it was a discharge
diagnosis or conﬁrmed more than twice in theby National Health Research Institutes. The inter-
of National Health Insurance, Department of Health,
ntributed equally to this work. Drs. Gregory Y.H. Lip
tin Fuster.
. Valentin Fuster.
mber 3, 2014, accepted November 11, 2014.
FIGURE 1 Flowchart of the Study Cohort Enrollment
NHIRD cohort (1996-2011)
More than 23 million enrollees
AF patients older than 20 years old
(n = 354,649)
AF patients without use of any
antiplatelet or anticoagulant agent
(n = 186,570)
AF females with a CHA2DS2-
VASc score of 1-2
AF males with a CHA2DS2-
VASc score of 0-1
CHA2DS2-VASc
score of 2
(n = 7,900)
CHA2DS2-VASc
score of 1
(n = 6,390)
CHA2DS2-VASc
score of 1
(n = 12,935)
CHA2DS2-VASc
score of 0
(n = 9,416)
Among 186,570 AF patients who were not receiving oral anticoagulant or antiplatelet
agents, there were 12,935 AF male patients with a CHA2DS2-VASc score of 1 and 7,900
AF female patients with a CHA2DS2-VASc score of 2. The risk of ischemic strokewas analyzed
for thesepatients and comparedwith thosewithout risk factors except female sex.AF¼ atrial
ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age 75 years or older,
diabetesmellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 74
years, female; NHIRD ¼ National Health Insurance Research Database.
TABLE 1 CHA2DS2-VASc Risk Factor Components of AF Patients
AF Male Patients
(n ¼ 12,935)
AF Female Patients
(n ¼ 7,900)
Age, yrs 59.1  11.3 59.1  10.2
CHA2DS2-VASc score 1 2
Risk factors according to
CHA2DS2-VASc
Congestive heart failure 2,016 (15.6) 1,347 (17.0)
Hypertension 4,075 (31.5) 2,756 (34.9)
Age 65–74 yrs 4,960 (38.3) 2,641 (33.4)
Diabetes mellitus 1,097 (8.5) 701 (8.9)
Vascular disease 787 (6.1) 455 (5.8)
Values are mean  SD or n (%) unless otherwise indicated.
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hypertension,
age 75 years or older, diabetes mellitus, previous stroke or transient ischemic
attack, vascular disease, age 65 to 74 years, female.
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637outpatient department (16). The diagnostic accuracy
of AF using this deﬁnition in the NHIRD was validated
previously (17,18).
The CHA2DS2-VASc score was calculated for each
patient by assigning 1 point each for age between 65
and 74 years; history of hypertension, diabetes,
recent cardiac failure, vascular disease (myocardial
infarction or peripheral artery disease); and female
sex. Two points each were assigned for a history of a
stroke, transient ischemic attack, or age 75 years or
older (2). We identiﬁed drug treatment status from
prescription claims from 180 days before to 90 days
after the AF diagnosis, excluding (as explained later)
patients who had a history of treatment with warfarin
or any antiplatelet agent, including aspirin, clopi-
dogrel, dipyridamole, and ticlopidine. Finally, a total
of 186,570 patients were enrolled in the study cohort
with 12,935 males having a CHA2DS2-VASc score of 1
and 7,900 females having a CHA2DS2-VASc score of 2.
A ﬂowchart of study enrollment is shown in Figure 1.
The reasons why we excluded patients who re-
ceived antithrombotic agents included that detailed
data about international normalized ratio and time in
therapeutic range for warfarin users were not recorded
in the NHIRD, and the lack of these parameters may
signiﬁcantly confound any analysis of ischemic stroke
risk; the main objective of the present study was to
analyze the risk of ischemic stroke in AF patients with
1 additional risk factor and to understand whether
OACs should be considered for stroke prevention in
these patients. This issue should ideally be studied in
patients without use of any antithrombotic agents.
Male AF patients with a CHA2DS2-VASc score of 1 and
female patients with a CHA2DS2-VASc score of 2 were
previously deﬁned as “low-moderate risk” and the use
of OACs for this level of risk is largely a recommen-
dation of recent guidelines only (10,19).
ENDPOINTS. The clinical endpoint was the occur-
rence of ischemic stroke, with concomitant imaging
studies of the brain including computed tomography
or magnetic resonance imaging. The accuracy of
diagnosis of ischemic stroke in Taiwan’s NHIRD has
been reported to be w94% (15). Another validation
study also demonstrated that the diagnostic accuracy
of ischemic stroke in NHIRD was high, with a positive
predictive value and sensitivity of 88.4% and 97.3%,
respectively (20).
STATISTICAL ANALYSIS. Data were presented as
the mean  SD for continuous variables and pro-
portions for categorical variables. An unpaired
2-tailed Student t test was used for the analysis of
continuous variables, and the differences between
nominal variables were compared by the chi-squaretest. The incidence rate of ischemic stroke was
calculated by dividing the number of events by
person-time at risk with the 95% conﬁdence interval
(CI) estimated by using the Fisher exact test. The
risk of ischemic stroke was assessed using the Cox
regression analysis. Statistical signiﬁcance was set
at p < 0.05, and all statistical analyses were carried
out by using SPSS 17.0 (SPSS, Chicago, Illinois).
TABLE 2 Risk of Isch
Risk Factor Component
the CHA2DS2-VASc Sco
Congestive heart failur
Hypertension
Age 65–74 yrs
Diabetes mellitus
Vascular disease
Total
*The risk of ischemic stro
regression analysis.
CI ¼ conﬁdence interval
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638RESULTS
The age and percentage of each risk factor of the
study patients are shown in Table 1. The mean ages
were 59.1  11.3 years for male patients and 59.1  10.2
years for female patients. Age between 65 and
74 years and hypertension were the most prevalent
risk factors for AF male and female patients,
respectively.
Among 12,935 AF male patients with a CHA2DS2-
VASc score of 1, there were 1,858 patients (14.4%) who
experienced ischemic stroke during follow-up (5.2 
4.3 years) with an annual stroke rate of 2.75%. The
risk of ischemic stroke ranged from 1.96%/year for
patients with vascular diseases to 3.50%/year for
those age 65 to 74 years of age (Table 2).
Compared with AF male patients with a CHA2DS2-
VASc score of 0, the hazard ratio of ischemic stroke
was 1.681 (95% CI: 1.333 to 2.120; p < 0.001) for pa-
tients with vascular diseases and increased to 3.085
(95% CI: 2.790 to 3.410; p < 0.001) for those 65 to
74 years of age (Table 2, Central Illustration).
Among the female patients with AF, 1,174 (14.9%)
experienced ischemic stroke during follow-up (5.9 
4.4 years), for an annual stroke rate of 2.55%. The risk
of ischemic stroke increased from 1.91%/year for pa-
tients with hypertension to 3.34%/year for those 65 to
74 years of age. Compared with AF female patients
with a CHA2DS2-VASc score of 1 (i.e., female sex only),
the hazard ratios of ischemic stroke ranged from
1.711 (95% CI: 1.481 to 1.976; p < 0.001) for patients
with hypertension to 3.031 (95% CI: 2.678 to 3.431)
for those 65 to 74 years of age (Table 3, Central
Illustration).
DISCUSSION
Our study is the ﬁrst population-based investi-
gation analyzing the risk of ischemic stroke in
nonanticoagulated AF male patients with a CHA2DS2-emic Stroke in AF Male Patients (CHA2DS2-VASc Score of 1)
s of
re
No. of
Events
Person-
Years
Annual
Stroke Rate
% (95% CI)
Hazard Ratio*
(95% CI) p Value
e 267 11,246 2.37 (2.10–2.67) 2.060 (1.788–2.373) <0.001
477 21,888 2.18 (1.99–2.38) 1.946 (1.731–2.189) <0.001
874 24,982 3.50 (3.27–3.74) 3.085 (2.790–3.410) <0.001
156 5,263 2.96 (2.52–3.47) 2.655 (2.230–3.161) <0.001
84 4,294 1.96 (1.56–2.42) 1.681 (1.333–2.120) <0.001
1,858 67,673 2.75 (2.62–2.87) 2.385 (2.184–2.604) <0.001
ke was compared with AF males with a CHA2DS2-VASc score of 0 using the Cox
; other abbreviations as in Table 1.VASc score of 1 and female patients with a CHA2DS2-
VASc score of 2, according to the speciﬁc covariates
composing the CHA2DS2-VASc score. We demon-
strated that AF male patients with only 1 risk factor
and a CHA2DS2-VASc score of 1 had an annual stroke
rate ranging between 1.96% and 3.50% depending on
the speciﬁc covariate composing the score. For AF
female patients with 1 additional stroke risk factor (a
CHA2DS2-VASc score of 2), the annual stroke rate
ranged from 1.91% to 3.34%.
In the study performed by Olesen et al. (3) using
the Danish nationwide cohort, the overall annual risk
of ischemic stroke was 1.51% and 3.01% for patients
with a CHA2DS2-VASc score of 1 and 2, respectively. In
the present study, our AF male patients with 1 risk
factor had a higher ischemic stroke risk (2.75%/year)
compared with the Danish data. Several reasons
might explain the difference. First, the Danish study
analyzed the overall risk of ischemic stroke in the
patient group with a CHA2DS2-VASc score of 1; this
included AF female patients without any additional
risk factors who were at low stroke risk. Second,
w34.7% of patients in the Danish cohort were
administered antiplatelet therapy, and the present
study excluded such patients. Third, Olesen et al. (3)
deﬁned their study endpoint as severe thromboem-
bolic events leading to hospital admission and death;
in our study; we deﬁned the clinical endpoint as
ischemic stroke regardless of severity.
As expected, not all risk factors in the CHA2DS2-
VASc score were associated with an equal risk
(Central Illustration). For AF male patients with a
CHA2DS2-VASc score of 1, the highest risk was seen in
those 65 to 74 years of age or those with diabetes
mellitus, which was also true for AF female patients
with a CHA2DS2-VASc score of 2. These ﬁndings were
consistent with those reported by Olesen et al. (3) in
the Danish nationwide study.
Vascular disease, including previous myocardial
infarction and peripheral vascular disease, was a
unique component of the CHA2DS2-VASc score that
was not included in other stroke risk scores, such as
CHADS2 (21), R2CHADS2 (renal dysfunction, conges-
tive heart failure, hypertension, age 75 years or older,
diabetes mellitus, previous stroke or transient
ischemic attack) (22), and the ATRIA (AnTicoa-
gulation and Risk factors In Atrial ﬁbrillation) score
(23). Vascular disease tends to be poorly recorded or
inconsistently deﬁned in older datasets, particularly
in nonwarfarin arms of the historical trial cohorts on
which (for example) the CHADS2 is based. Previous
studies demonstrated that vascular disease was an
independent risk factor for thromboembolic events in
AF (24,25), even among Chinese AF patients (8,26).
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For male patients with a CHA2DS2-VASc score of 1 and female patients with a CHA2DS2-VASc score of 2, hazard ratios of ischemic stroke varied
depending on individual risk factors but were highest for patients between 65 and 74 years of age compared with male patients with a
CHA2DS2-VASc score of 0 and female patients with a CHA2DS2-VASc score of 1 (accounting for female sex). *The risk of ischemic stroke was
compared in AF male patients with a CHA2DS2-VASc score of 0 and AF female patients with a CHA2DS2-VASc score of 1. AF ¼ atrial ﬁbrillation;
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack,
vascular disease, age 65 to 74 years, female; CI ¼ conﬁdence interval.
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639The ﬁndings of the present study conﬁrm that for AF
patients with vascular disease alone without addi-
tional risk factors, the risk of ischemic stroke would
be signiﬁcantly increased, by 1.68-fold and 2.15-fold
for male and female patients, respectively.
CLINICAL IMPLICATIONS. Decisions about whether
to use OACs for stroke prevention should be basedon the net clinical beneﬁt balancing stroke re-
duction with major bleeding. In recent years, several
non–vitamin K antagonist OACs (e.g., dabigatran,
rivaroxaban, apixaban) became available, and all are
at least as effective as warfarin in stroke prevention
and are much safer in the risk of intracranial hemor-
rhage compared to warfarin, with the annual rate
ranging from 0.23% to 0.50% (27–30) (Figure 2). The
TABLE 3 Risk of Ischemic Stroke in AF Female Patients (CHA2DS2-VASc Score of 2:
Female Plus 1 Additional Stroke Risk Factor)
Risk Factor Components of
the CHA2DS2-VASc Score
No. of
Events
Person-
Years
Annual
Stroke Rate
% (95% CI)
Hazard Ratio*
(95% CI) p Value
Congestive heart failure 181 8,151 2.22 (1.91–2.57) 1.984 (1.672–2.353) <0.001
Hypertension 303 15,864 1.91 (1.70–2.14) 1.711 (1.481–1.976) <0.001
Age 65–74 yrs 521 15,602 3.34 (3.06–3.64) 3.031 (2.678–3.431) <0.001
Diabetes mellitus 110 3,823 2.88 (2.37–3.47) 2.655 (2.158–3.267) <0.001
Vascular disease 59 2,618 2.25 (1.72–2.91) 2.152 (1.641–2.823) <0.001
Total 1,174 46,058 2.55 (2.41–2.70) 2.251 (2.024–2.504) <0.001
*The risk of ischemic stroke was compared with AF female patients with a CHA2DS2-VASc score of 1 (only due
to the female sex) using the Cox regression analysis.
Abbreviations as in Tables 1 and 2.
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640improvements in convenience and safety of non–
vitamin K antagonist OACs compared with warfarin
may lower the threshold for initiating OAC treatment
for AF patients (31,32).
The focus of stroke risk stratiﬁcation has shifted
to initially identifying patients with a truly low
risk of ischemic stroke for whom OACs are not rec-
ommended (33). According to the 2012 updated ESCFIGURE 2 ICH Rates With Use of NOACs
Patients Receiving NOACs in Randomized Trials*
An
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)
Dabigatran 150 mg
Dabigatran 110 mg
Apixaban 5/2.5 mg
Rivaroxaban 20/15 mg
Edoxaban 60 mg
Edoxaban 30 mg
2
1
0
3
0.23 0.30
0.50
0.33 0.26
0.39
In addition to being as effective as warfarin in stroke prevention
in patients with atrial ﬁbrillation, NOACs also present less risk in
terms of ICH according to data from randomized trials. *RE-LY
(Randomized Evaluation of Long-Term Anticoagulation Therapy),
ROCKET-AF (Rivaroxaban Once-daily, oral, direct factor Xa
inhibition Compared with vitamin K antagonism for prevention
of stroke and Embolism Trial in Atrial Fibrillation), ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation), and ENGAGE AF-TIMI 48 (Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation–Thrombolysis In Myocardial Infarction 48). ICH ¼
intracranial hemorrhage; NOACs ¼ non–vitamin K antagonist
oral anticoagulant agent(s).guidelines, OACs should be prescribed for all AF pa-
tients with $1 additional stroke risk factors, except
for those with a CHA2DS2-VASc score of 0 (male pa-
tients) and female patients with their sex as the single
risk factor who fulﬁll the criteria of age younger than
65 and “lone AF” (10). Nonetheless, the evidence
supporting the recommendation regarding OAC use
for AF male patients with a single risk factor and a
CHA2DS2-VASc score of 1 was relatively limited, and
the 2014 ACC/AHA AF guideline recommendation for
these patients of “no antithrombotic therapy, aspirin,
or OAC” can be considered (12).
Because AF male patients with a CHA2DS2-VASc
score of 1 still account for a considerable percentage
of the AF population (around 6.9% in the Taiwan
NHIRD), how to manage these patients with regard to
stroke prevention is an important issue. In the pre-
sent study, the annual stroke rate was 2.75% (1.96% to
3.5%) for male patients with a CHA2DS2-VASc score of
1, which was much higher than the risk of intracranial
hemorrhage (0.23% to 0.50% per year) or signiﬁcant
bleeding (0.25% to 1.45% per year) due to non–
vitamin K antagonist OACs (27–30). Therefore, our
ﬁndings support the ESC and National Institute for
Health and Care Excellence guidelines suggesting
that OACs should be prescribed for all AF patients
with 1 additional stroke risk factor given their high
risk of ischemic stroke (10,13). However, the results
reported here were derived from an epidemiological
study, and the net clinical beneﬁt balancing
stroke reduction against major bleeding remains to
be deﬁned. Nonetheless, serious bleeding risks in
patients with a CHA2DS2-VASc score of 1 (males) or
2 (females) are low (34).
OTHER POTENTIAL RISK FACTORS FOR ISCHEMIC
STROKE. Recently, several studies have reported the
potential relationship between left atrial structures
and risk of ischemic stroke in AF (35–37). Daccarett
et al. (35) found that left atrial ﬁbrosis detected by
magnetic resonance imaging was closely associated
with the CHADS2 score and a history of stroke in AF
patients. In a multicenter study enrolling 932 AF pa-
tients who were planning to undergo catheter abla-
tion, the morphology of left atrial appendages was
categorized into 4 types (cactus, chicken wing,
windsock, and cauliﬂower) by computed tomography
and magnetic resonance imaging (36). The authors
found that patients with “chicken wing” left atrial
appendage morphology are less likely to have an
embolic event. Another study performed by Kimura
et al. (37) demonstrated that a “cauliﬂower” left atrial
appendage was signiﬁcantly more common in pa-
tients with stroke. Additional research is necessary to
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Oral anticoagulation
should be considered for patients with atrial ﬁbrillation and
1 additional stroke risk factor (men with CHA2DS2-VASc
scores $1 and women with scores $2) to reduce their risk
of ischemic stroke.
TRANSLATIONAL OUTLOOK: Future studies should attempt
to deﬁne the net clinical beneﬁt of anticoagulation, balancing
prevention of both thromboembolism and major bleeding, for
patients with AF who have 1 stroke risk factor in addition to sex,
recognizing that this may be inﬂuenced by the type of agent
used and the intensity of therapy.
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641determine whether incorporating these factors into
the scoring scheme could further reﬁne stroke risk
stratiﬁcation in AF.
STUDY LIMITATIONS. First, the type of AF (parox-
ysmal or nonparoxysmal) was not available from this
nationwide dataset. However, because evidence
suggests the risk of stroke does not differ between
patients with paroxysmal or nonparoxysmal AF
(38,39), the type of AF may not confound the ﬁndings
of this study. Second, patients who did not receive
antithrombotic agents at enrollment could possibly
take OACs during follow-up, which would prevent the
occurrence of ischemic stroke. Because these patients
were not censored from the analysis, the true risk of
ischemic stroke for patients not taking OACs during
the whole study period could be higher than what we
report here. Therefore, the underrecognition of OAC
use during follow-up would not change the principal
ﬁnding of the present study, which suggests that
OACs should be considered for all AF patients with 1
additional stroke risk factor. Third, the diagnosis of
AF and the occurrence of ischemic stroke were based
on the diagnostic codes registered by the physicians
responsible for treating these patients; nonetheless,
the accuracy of AF and ischemic stroke diagnosis in
Taiwan’s NHIRD has been previously validated to be
high (15,17,18,20). Last, we were not able to clearly
conﬁrm the cause of ischemic stroke because it can be
due to AF-related thromboembolism or atheroscle-
rosis and thrombosis of the cerebral artery. However,
this has been a common limitation in previous ran-
domized trials as well (27–29).CONCLUSIONS
In this real-world national cohort of AF patients not
receiving anticoagulant therapy, the risk of ischemic
stroke was >2.5%/year for AF patients with 1 addi-
tional stroke risk factor (a CHA2DS2-VASc score of
1 [males] or 2 [females]). OACs should be considered
for AF patients with 1 additional stroke risk factor
given their high risk of ischemic stroke.
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